Healthcare resource use in advanced prostate cancer patients treated with docetaxel

Journal of Medical Economics

Volumn 15, Issue 5, 2012, Pages 836-843

  Mehra, Maneesha ^a   Wu, Ying ^b   Dhawan, Ravinder ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b Janssen Global Services   (United States)

Author keywords

Chemotherapy; Cost; Health economics; Health outcomes; Metastatic castrate resistant prostate cancer; Retrospective cohort study

Indexed keywords

ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; DOCETAXEL; ESTRAMUSTINE; KETOCONAZOLE; MITOXANTRONE; NAVELBINE; OPIATE DERIVATIVE; PREDNISONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; COST OF ILLNESS; EMERGENCY WARD; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; PRESCRIPTION; RETROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; HEALTH RESOURCES; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TAXOIDS; UNITED STATES;

EID: 84865249876     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.681718     Document Type: Article

References (22)

1. American Cancer Society. Cancer facts & figures, 2010. American Cancer Society Web site. http://www.cancer.org/acs/groups/content/ @epidemiologysurveilance/documents/document/acspc-026238.pdf. Accessed November 4, 2011
2. Horwich A, Parker C, Kataja V. Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(4 Suppl):76-8
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2009;59:225-49
4. Martel CL, Gumerlock PH, Meyers FJ, et al. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 2003;29:171-87
5. Taxotere (docetaxel) injection concentrate prescribing information. Bridgewater, NJ: Sanofi-Aventis U.S. LLC, 2010
6. Tannock IF, de WR, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12
7. Mohler JL, Armstrong AJ, Bahnson RR, et al. National Comprehensive Cancer Network. Prostate cancer treatment guidelines. Version 4. 2011. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp. Accessed November 13, 2011
8. Hwang SS, Chang VT, Alejandro Y, et al. Study of hormone refractory prostate cancer: Hospital care and palliative care resource use at a VA medical center. Cancer Invest 2004;22:849-57
9. Oglesby A, Pockett RD, McEwan P, et al. Hospital burden of disease associated with metastatic bone disease (MBD) and skeletal-related events (SREs) in patients with breast cancer (BC) and prostate cancer (PC) in the United Kingdom. Presented at: ISPOR 11th Annual European Congress; November 8-11, 2008. Athens, Greece. Abstract PCN54
10. Oglesby A, Pockett RD, McEwan P, et al. Hospital burden of disease associated with metastatic bone disease (MBD) and skeletal-related events (SREs) in patients with breast cancer (BC) and prostate cancer (PC) in Spain. ISPOR 11th Annual European Congress; November 8-11, 2008. Athens, Greece. Abstract PCN56
11. Piper NY, Kusada L, Lance R, et al. Adenocarcinoma of the prostate: An expensive way to die. Prostate Cancer Prostatic Dis 2002;5:164-6
12. Alemayehu B, Buysman E, Parry D, et al. Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population. J Med Econ 2010;13:351-61
13. Cox F, Khan ZM, Schweinle JE, et al. Cost associated with the treatment of influenza in a managed care setting. MedGenMed 2000;2:E34
14. Crawford ED, Black L, Eaddy M, et al. A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer. Prostate Cancer Prostatic Dis 2010;13:162-7
15. Davis KL, Misurski D, Miller JM, et al. Cost of acute hospitalization and postdischarge follow-up care for meningococcal disease in the US. Hum Vaccin 2011;7:96-101
16. Gore M, Zlateva G, Tai KS, et al. Retrospective evaluation of clinical characteristics, pharmacotherapy and healthcare resource use among patients prescribed pregabalin or duloxetine for diabetic peripheral neuropathy in usual care. Pain Pract 2011;11:167-79
17. Vekeman F, McKenzie RS, Bookhart BK, et al. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: Observations from a large managed-care database. J Med Econ 2009;12:1-8
18. Stokes ME, Black L, Benedict A, et al. Long-term medical-care costs related to prostate cancer: Estimates from linked SEER-Medicare data. Prostate Cancer Prostatic Dis 2010;13:278-84
19. Sherman EJ, Pfister DG, Ruchlin HS, et al. The Collection of Indirect and Nonmedical Direct Costs (COIN) form: A new tool for collecting the invisible costs of androgen independent prostate carcinoma. Cancer 2001;91:841-53
20. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: A systematic review. Int J Clin Pract 2011;65:1180-92
21. Engel-Nitz NM, Alemayehu B, Parry D, et al. Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population. Cancer Manag Res 2011;3:233-45
22. Beetsch J, Combates N, Nicacio, L. Castrate-resistant prostate cancer: Clinical as well as economic factors should influence treatment practice. Presented at: European Multidisciplinary Cancer Congress (ECCO); 23-27 September, 2011. Stockholm, Sweden